Bavarian Nordic updates phase III booster study plans, sets launch for August

The biotech firm aims to compare its Covid-19 vaccine candidate, ABNCoV2, with Pfizer/Biontech’s Comirnaty in a controlled, double-blind trial.

Photo: Sven Hoppe/AP/Ritzau Scanpix

Bavarian Nordic has scheduled its phase III trial of its booster candidate against Covid-19, dubbed ABNCoV2, in August, according to a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs